FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,899 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $20.55, for a total value of $388,374.45. Following the completion of the transaction, the chief executive officer now owns 3,370,103 shares in the company, valued at approximately $69,255,616.65. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
FibroGen Inc. (NASDAQ:FGEN) traded up 1.07% on Wednesday, hitting $20.73. The stock had a trading volume of 271,802 shares. FibroGen Inc. has a one year low of $14.38 and a one year high of $31.90. The stock’s 50 day moving average is $19.60 and its 200 day moving average is $18.68. The stock’s market cap is $1.30 billion.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. Analysts anticipate that FibroGen Inc. will post ($1.25) earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new stake in FibroGen during the second quarter valued at approximately $106,000. Acrospire Investment Management LLC boosted its stake in FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 4,700 shares during the period. Teacher Retirement System of Texas boosted its stake in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 937 shares during the period. Quantbot Technologies LP bought a new stake in FibroGen during the second quarter valued at approximately $164,000. Finally, Fox Run Management L.L.C. bought a new stake in FibroGen during the second quarter valued at approximately $176,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
Separately, Credit Suisse Group AG restated a “buy” rating on shares of FibroGen in a report on Tuesday, July 12th.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.